In MS patients, CB74 and VL23 exerted a similar inhibition of the expression of CD69 and CD54, even better than that observed in control subjects, while AF4 was less efficient than the other compounds in inhibiting CD69 and had little effect on CD54 levels (Fig. 4B). This evidence concerns the gene ICAM1 and myeloid sarcoma.